Pulmonary Diseases
Pulmonary Diseases(肺部疾病)
Pulmonary Diseases 相关产品(105)
- GC44054Leukotriene C4 methyl esterCAS: 73958-10-8纯度: >97.00%
A more lipid soluble formulation of LTE 4
- GC44696Prolyl-glycyl-proline Peptide纯度: >95.00%
A biomarker for chronic obstructive pulmonary disease and cystic fibrosis
- GC45409Ciclesonide-d7CAS: 1225382-70-6纯度: >99.00%
An internal standard for the quantification of ciclesonide
- GC45455Fluticasone 17β-Carboxylic AcidCAS: 28416-82-2纯度: >98.00%
An intermediate in the synthesis of fluticasone propionate
- GC45536Oleic Acid-13CCAS: 82005-44-5纯度: >98.00%
An internal standard for the quantification of oleic acid
- GC45558Salbutamol-d9CAS: 1173021-73-2纯度: >99.00%
An internal standard for the quantification of salbutamol
- GC45795Aztreonam-d6CAS: 1127452-94-1纯度: >99.00%
An internal standard for the quantification of aztreonam
- GC45819Indacaterol-d3CAS: 2699828-16-3纯度: >99.00%
An internal standard for the quantification of indacaterol
- GC46134Dityrosine (hydrochloride)CAS: 2716849-01-1纯度: >95.00%
A neuropeptide with diverse biological activities
- GC46313(±)-α-Tocopherol Acetate-d3CAS: 2742364-46-9纯度: >99.00%
A neuropeptide with diverse biological activities
- GC46956Budesonide-d8CAS: 1105542-94-6纯度: >98.00%
An internal standard for the quantification of budesonide
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC43751 | GHK | 49557-75-7 | >98.00% | |
An ECM-derived peptide | ||||
| GC44054 | Leukotriene C4 methyl ester | 73958-10-8 | >97.00% | |
A more lipid soluble formulation of LTE 4 | ||||
| GC44055 | Leukotriene D4 methyl ester | - | >97.00% | |
A more lipid soluble formulation of LTD 4 | ||||
| GC44056 | Leukotriene E4 methyl ester | - | >97.00% | |
A more lipid soluble formulation of LTE 4 | ||||
| GC44540 | PAF C-16 Carboxylic Acid | 129879-41-0 | >95.00% | |
PAF with a reactive carboxylic acid group | ||||
| GC44541 | PAF C-18 | 74389-69-8 | >97.00% | |
A natural PAF analog | ||||
| GC44696 | Prolyl-glycyl-proline Peptide | - | >95.00% | |
A biomarker for chronic obstructive pulmonary disease and cystic fibrosis | ||||
| GC44868 | Salbutamol (hydrochloride) | 50293-90-8 | >98.00% | |
A β 2 -AR agonist | ||||
| GC45057 | TIQ-A | 420849-22-5 | >98.00% | |
A PARP1 inhibitor | ||||
| GC45409 | Ciclesonide-d7 | 1225382-70-6 | >99.00% | |
An internal standard for the quantification of ciclesonide | ||||
| GC45455 | Fluticasone 17β-Carboxylic Acid | 28416-82-2 | >98.00% | |
An intermediate in the synthesis of fluticasone propionate | ||||
| GC45536 | Oleic Acid-13C | 82005-44-5 | >98.00% | |
An internal standard for the quantification of oleic acid | ||||
| GC45558 | Salbutamol-d9 | 1173021-73-2 | >99.00% | |
An internal standard for the quantification of salbutamol | ||||
| GC45692 | Cholesteryl Palmitate-d9 | - | >99.00% | |
A neuropeptide with diverse biological activities | ||||
| GC45706 | GHK-Cu (acetate) | 300801-03-0 | >98.00% | |
A tripeptide-copper(II) complex | ||||
| GC45768 | Pranlukast-d4 | 2713172-43-9 | >99.00% | |
A neuropeptide with diverse biological activities | ||||
| GC45795 | Aztreonam-d6 | 1127452-94-1 | >99.00% | |
An internal standard for the quantification of aztreonam | ||||
| GC45819 | Indacaterol-d3 | 2699828-16-3 | >99.00% | |
An internal standard for the quantification of indacaterol | ||||
| GC45993 | Terbutaline | 23031-25-6 | >98.00% | |
Terbutaline是一种新型的选择性肾上腺素β2受体激动剂。 | ||||
| GC46134 | Dityrosine (hydrochloride) | 2716849-01-1 | >95.00% | |
A neuropeptide with diverse biological activities | ||||
| GC46313 | (±)-α-Tocopherol Acetate-d3 | 2742364-46-9 | >99.00% | |
A neuropeptide with diverse biological activities | ||||
| GC46583 | 3-Amino-2,6-Piperidinedione | 2353-44-8 | >95.00% | |
An active metabolite of (±)-thalidomide | ||||
| GC46924 | BIBF 1120-13C-d3 | - | >99.00% | |
A neuropeptide with diverse biological activities | ||||
| GC46956 | Budesonide-d8 | 1105542-94-6 | >98.00% | |
An internal standard for the quantification of budesonide | ||||